David D’Alessio

David D’Alessio, chief of endocrinology and metabolism at Duke University, and Randy Seeley, a professor at the University of Michigan, delve into the groundbreaking GLP-1 drugs like Ozempic. They reveal these drugs’ potential to combat not just Type 2 diabetes and obesity, but also addictions, migraines, and even neurological diseases like Alzheimer’s. The discussion uncovers the science behind why these medications perform so many functions and considers the implications of making them more widely available for general health.

In this enlightening discussion, David D'Alessio, Chief of Endocrinology at Duke University, and Randy Seeley, Professor at the University of Michigan, dive deep into the world of GLP-1 drugs. They explore how these medications promote weight loss by increasing satiety and affecting brain-gut communication. The pair also discuss the surprising shift from diabetes treatments to weight-loss solutions and the potential benefits for cardiovascular health. Plus, they ponder the drugs' effects on cravings and the importance of personalizing treatment approaches.